PURPOSE: The purpose of this retrospective study was to evaluate cardiac troponin-I (cTnI) as a 28-day mortality prognosticator and predictor for a drotrecogin alfa (activated) (DrotAA) survival benefit in recombinant human activated Protein C Worldwide Evaluation in Severe Sepsis patients. METHODS: Cardiac troponin-I was measured using the Access AccuTnI Troponin I assay (Beckman Coulter, Fullerton, CA). There were 598 patients (305 DrotAA, 293 placebo) with baseline cTnI data (cTnI negative [<0.06 ng/mL], n = 147; cTnI positive [>or=0.06 ng/mL], n = 451). RESULTS: Cardiac troponin-I-positive patients were older (mean age, 61 vs 56 years; P = .002), were sicker (mean Acute Physiology and Chronic Health Evaluation II, 26.1 vs 22.3; P < .001), had lower baseline protein C levels (mean level, 49% vs 56%; P = .017), and had higher 28-day mortality (32% vs 14%, P < .0001) than cTnI-negative patients. Elevated cTnI was an independent prognosticator of mortality (odds ratio, 2.020; 95% confidence interval, 1.153-3.541) after adjusting for other significant variables. Breslow-Day interaction test between cTnI levels and treatment was not significant (P = .65). CONCLUSION: This is the largest severe sepsis study reporting an association between elevated cTnI and higher mortality. Cardiac troponin-I elevation was not predictive of a survival benefit with DrotAA treatment. Copyright (c) 2010 Elsevier Inc. All rights reserved.
PURPOSE: The purpose of this retrospective study was to evaluate cardiac troponin-I (cTnI) as a 28-day mortality prognosticator and predictor for a drotrecogin alfa (activated) (DrotAA) survival benefit in recombinant human activated Protein C Worldwide Evaluation in Severe Sepsispatients. METHODS:Cardiac troponin-I was measured using the Access AccuTnI Troponin I assay (Beckman Coulter, Fullerton, CA). There were 598 patients (305 DrotAA, 293 placebo) with baseline cTnI data (cTnI negative [<0.06 ng/mL], n = 147; cTnI positive [>or=0.06 ng/mL], n = 451). RESULTS:Cardiac troponin-I-positive patients were older (mean age, 61 vs 56 years; P = .002), were sicker (mean Acute Physiology and Chronic Health Evaluation II, 26.1 vs 22.3; P < .001), had lower baseline protein C levels (mean level, 49% vs 56%; P = .017), and had higher 28-day mortality (32% vs 14%, P < .0001) than cTnI-negative patients. Elevated cTnI was an independent prognosticator of mortality (odds ratio, 2.020; 95% confidence interval, 1.153-3.541) after adjusting for other significant variables. Breslow-Day interaction test between cTnI levels and treatment was not significant (P = .65). CONCLUSION: This is the largest severe sepsis study reporting an association between elevated cTnI and higher mortality. Cardiac troponin-I elevation was not predictive of a survival benefit with DrotAA treatment. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: Francis Bessière; Safia Khenifer; Julie Dubourg; Isabelle Durieu; Jean-Christophe Lega Journal: Intensive Care Med Date: 2013-04-18 Impact factor: 17.440
Authors: Jennifer H Jordan; Ralph B D'Agostino; Craig A Hamilton; Sujethra Vasu; Michael E Hall; Dalane W Kitzman; Vinay Thohan; Julia A Lawrence; Leslie R Ellis; Timothy L Lash; W Gregory Hundley Journal: Circ Cardiovasc Imaging Date: 2014-10-01 Impact factor: 7.792
Authors: Gordon E Carr; Trevor C Yuen; John F McConville; John P Kress; Terry L VandenHoek; Jesse B Hall; Dana P Edelson Journal: Chest Date: 2011-12-22 Impact factor: 9.410
Authors: Osamu Takasu; Joseph P Gaut; Eizo Watanabe; Kathleen To; R Eliot Fagley; Brian Sato; Steve Jarman; Igor R Efimov; Deborah L Janks; Anil Srivastava; Sam B Bhayani; Anne Drewry; Paul E Swanson; Richard S Hotchkiss Journal: Am J Respir Crit Care Med Date: 2013-01-24 Impact factor: 21.405
Authors: Brandon C Drafts; Katie M Twomley; Ralph D'Agostino; Julia Lawrence; Nancy Avis; Leslie R Ellis; Vinay Thohan; Jennifer Jordan; Susan A Melin; Frank M Torti; William C Little; Craig A Hamilton; W Gregory Hundley Journal: JACC Cardiovasc Imaging Date: 2013-05-01